Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.32 |
| ▸ | RELA | Q04206 | 2/20 | 0.32 |
| ▸ | JUN | P05412 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | ULK1 | O75385 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30462039 | 0.81 | CSNK1A1 (0.46) | LRRK2SMN1; SMN2KDM4EALDH1A1CSNK1A1 | |
| SCHEMBL26627777 | 0.81 | CSNK1A1 (0.46) | LRRK2SMN1; SMN2KDM4EALDH1A1CSNK1A1 | |
| SCHEMBL31456643 | 0.81 | LRRK2 (0.36) | LRRK2SMN1; SMN2KDM4EALDH1A1CSNK1A1 | |
| SCHEMBL1916564 | 0.80 | KDM4E (0.38) | SMN1; SMN2KDM4EALDH1A1NFKB1NFKB2 | |
| SCHEMBL31456685 | 0.77 | LRRK2 (0.34) | LRRK2SMN1; SMN2KDM4EALDH1A1NFKB1 | |
| SCHEMBL24978008 | 0.77 | LRRK2 (0.36) | LRRK2SMN1; SMN2KDM4EALDH1A1CSNK1A1 | |
| SCHEMBL31254690 | 0.73 | ALDH1A1 (0.35) | SMN1; SMN2KDM4EALDH1A1NFKB1NFKB2 | |
| SCHEMBL145005 | 0.72 | ALDH1A1 (0.55) | SMN1; SMN2KDM4EALDH1A1NFKB1NFKB2 | |
| SCHEMBL29556850 | 0.72 | ALDH1A1 (0.55) | SMN1; SMN2KDM4EALDH1A1NFKB1NFKB2 | |
| SCHEMBL28242275 | 0.72 | GRIN1 (0.35) | LRRK2SMN1; SMN2NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741386-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20250289799-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2025-09-18 | — | — | US | disclosed |
| CN-119998271-A | Pyridone compound and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025067126-A1 | PYRIDONE COMPOUNDS AND PREPARATION METHOD THEREFOR, AND APPLICATION | 深圳信立泰药业股份有限公司 | 2025-04-03 | — | — | WO | disclosed |
| EP-4516779-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
| EP-4511368-A2 | CCR4 ANTAGONISTS | ChemoCentryx, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2025007777-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2025-01-09 | — | — | WO | disclosed |
| WO-2024233665-A1 | COMPOUNDS AND THEIR USE AGAINST CANCER | TANGO THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2024208292-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITOR, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2024-10-10 | — | — | WO | disclosed |
| CN-118660872-A | Pyrimidine compound, preparation method and medical application thereof | 江苏亚虹医药科技股份有限公司 | 2024-09-17 | — | — | CN | disclosed |
| WO-2024125451-A1 | PIPERINDIN-ONES DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-06-20 | — | — | WO | disclosed |
| US-20230382894-A1 | CCR4 ANTAGONISTS | CHEMOCENTRYX, INC. | 2023-11-30 | — | — | US | disclosed |
| WO-2023208130-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2023-11-02 | — | — | WO | disclosed |
| WO-2023205618-A2 | CCR4 ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| CN-116496252-A | Pyrimidine compound, preparation method and medical application thereof | 江苏亚虹医药科技股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382894-A1 | CCR4 ANTAGONISTS | CCR4, CCR1, CCR3 | LRRK2 2983/4885SMN1; SMN2 1867/4885KDM4E 1342/4885 |
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP4F11, CYP4A11, HSD11B1 | LRRK2 2573/4885SMN1; SMN2 4572/4885KDM4E 2018/4885 |
| US-20250289799-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | USP1, UPP1, UFL1 | LRRK2 3534/4885SMN1; SMN2 2646/4885KDM4E 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.